There is a citation in PREMEDLINE on Donepezil:

UI  - 97072226
AU  - Rogers SL ; Friedhoff LT
TI  - The efficacy and safety of donepezil in patients with Alzheimer's
      disease: results of a US Multicentre, Randomized, Double-Blind,
      Placebo-Controlled Trial. The Donepezil Study Group [In Process
LA  - Eng
DA  - 961126
DP  - 1996 Nov-Dec
IS  - 1013-7424
TA  - Dementia
RO  - O:099
PG  - 293-303
SB  - M
IP  - 6
VI  - 7
AB  - This study evaluated the efficacy and safety of donepezil in
      patients with mild to moderately severe Alzheimer's disease, and
      examined the relationships between plasma donepezil
      concentration, red blood cell acetylcholinesterase (AChE)
      activity and clinical response. The trial was of a multicenter,
      double-blind, parallel-group design and patients were randomised
      to once-daily treatment with either donepezil (1, 3 or 5 mg) or
      placebo. The 12-week double-blind phase was followed by a 2-week
      single-blind placebo washout. 161 patients (55-85 years of age)
      entered the study and 141 completed treatment. Patients treated
      with donepezil showed dose-related improvements in the
      Alzheimer's Disease Assessment Scale-cognitive subscale score
      (ADAS-cog) and in MMSF scores. The improvements in ADAS-cog were
      statistically significantly greater with donepezil 5 mg/day than
      with placebo. There was a 50% reduction in the percentage of
      patients showing clinical decline with donepezil at 5 mg/day
      (11%) relative to placebo (20%). In addition, a statistically
      significant correlation between plasma concentrations of
      donepezil and AChE inhibition was demonstrated. A plateau of
      inhibition (76-84%) was reached at plasma donepezil
      concentrations > 50 ng/ml. The correlation between plasma drug
      concentrations and ADAS-cog (p = 0.014), MMSE (p = 0.023) and
      patient quality of life scores, assessed by the patient (p =
      0.037) were also statistically significant, as was the
      correlation between AChE inhibition and change in ADAS-cog (p =
      0.008). The incidence of treatment-emergent adverse events with
      all three dosages of donepezil (64-68%) was comparable to that
      observed with placebo (65%). Donepezil had no clinically
      significant effect on vital signs, haematology or clinical
      biochemistry tests. Importantly, donepezil was not associated
      with any hepatotoxicity, as observed with acridine-based
      cholinesterase inhibitors.
AD  - Department of Clinical Research, Eisai America Inc., Teaneck,
      N.J. 07666-6741, USA.
SO  - Dementia 1996 Nov-Dec;7(6):293-303

At 11:00 PM 1/23/97 +0530, you wrote:

>On Thu, 23 Jan 1997, John Sayarath wrote:
> Would any of you be so kind to direct me to review articles on new drug
> called Donepezil, or Aricept for trade name? It is a new drug for
> Alzheimer's disease. Thanks.
> B. John Sayarath, AB, MST
> Medical Librarian             voice:  802-334-3256
> North Country Hospital
> RR 3 Box 124 Prouty Drive       fax:  802-334-3240
> Newport, Vermont 05855        email:  [log in to unmask]

Kathel Dunn
Information Specialist
New York Academy of Medicine
1216 Fifth Avenue
New York, NY  10029

[log in to unmask]